Abstract Countries in the Greater Mekong sub-region (GMS) have been encouraged to deploy mass chloroquine treatments given monthly for four months to reduce the burden of vivax malaria. This paper summarizes briefly current knowledge on Plasmodium vivax epidemiology, the biology of vivax relapse and previous experience using dihydroartemisinin–piperaquine mass treatments in the GMS to show why this approach would be extremely cost-ineffective. Around 800 full treatment courses in 200 people would be needed to prevent one symptomatic case. Mass chloroquine treatment will contribute little or nothing to the elimination of vivax malaria in this area.
Ghulam Rahim Awab, Sasithon Pukrittayakamee, Mallika Imwong, Arjen M. Dondorp, Charles J. Woodrow, Sue Jean Lee, Nicholas Day, Pratap Singhasivanon, Sir Nicholas White, Faizullah Kaker
Ghulam Rahim Awab, Sasithon Pukrittayakamee, Mallika Imwong, Arjen M. Dondorp, Charles J. Woodrow, Sue Jean Lee, Nicholas Day, Pratap Singhasivanon, Sir Nicholas White, Faizullah Kaker
Phung Duc Thuan, Nguyen Thuy Nha Ca, Pham Van Toi, Thuy-Nhien Nguyen, Ngo Viet Thanh, Nguyen Duc Anh, Nguyen Hoan Phu, Cao Quang Thai, Le Hong Thai, Nhu Thi Hoa, Le Thanh Dong, Mai Anh Loi, Do Hung Son, Tran Tinh Ngoc Khanh, Christiane Dolecek, Ho Thi Nhan, Marcel Wolbers, Guy Thwaites, Jeremy Farrar, Sir Nicholas White, Tran Tinh Hien
Aung Pyae Phyo, Khin Maung Lwin, Ric N. Price, Elizabeth A. Ashley, Bruce Russell, Kanlaya Sriprawat, Niklas Lindegårdh, Pratap Singhasivanon, Sir Nicholas White, François Nosten
Sornchai Looareesuwan, Polrat Wilairatana, S Krudsood, Sombat Treeprasertsuk, Pratap Singhasivanon, Valai Bussaratid, W. Chokjindachai, Parnpen Viriyavejakul, K Chalermrut, Douglas S. Walsh, Sir Nicholas White
Discussion(0)
No comments yet. Be the first to comment.